Zentiva Strikes Deal To Buy UK’s Creo Pharmaceuticals As It Pursues ‘Champion’ Ambitions
Zentiva has announced it is buying the UK’s Creo Pharmaceuticals from Amneal Pharmaceuticals as it pursues its goal of becoming a European generics leader.
You may also be interested in...
Zentiva is opening a dedicated Indian office in Mumbai to support the Ankleshwar manufacturing facility that it has just acquired from former parent company Sanofi.
Alvogen’s central and eastern European business, which started up in 2010, has now been sold to the Zentiva group. Zentiva plans to combine both companies’ branded generics and OTC businesses in the CEE region.
In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.